Enterprise Value

182M

Cash

92.46M

Avg Qtr Burn

-8.14M

Short % of Float

0.26%

Insider Ownership

0.00%

Institutional Own.

0.17%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
LUMOXITI Details
Leukemia, Cancer

Approved

Quarterly sales

Monalizumab + durvalumab + oleclumab Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

Phase 3

Update

Phase 2

Data readout

IPH5201 Details
Lung cancer, Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

Lacutamab (IPH4102) + GEMOX Details
Cancer, Lymphoma, Peripheral T cell cancer

Phase 2

Data readout

Lacutamab (IPH4102) Details
Lymphoma, Cancer, Mycosis fungoides

Phase 2

Data readout

Lacutamab (IPH4102) Details
Lymphoma, Sezary syndrome, Cancer

Phase 2

Update

Avdoralimab (IPH5401) Details
COVID-19, Infectious disease

Phase 2

Update

IPH6401 / SAR’514 Details
Cancer, Multiple myeloma, relapsed or refractory light chain amyloidosis, Post-stroke recovery

Phase 1/2

Data readout

IPH6101 / SAR443579 Details
Cancer, Relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia

Phase 1/2

Data readout

IPH6501 Details
Cancer, Non-Hodgkin lymphoma

Phase 1/2

Data readout

Lacutamab (IPH4102) Details
Cancer, Lymphoma, Peripheral T cell cancer

Phase 1b

Data readout

IPH5301 (anti-CD73) Details
Cancer, Solid tumor/s

Phase 1

Data readout

Avdoralimab (IPH5401) Details
Bullous pemphigoid , Skin disease/disorder

Failed

Discontinued

Monalizumab (anti-NKG2A) Details
Head and neck cancer, Head and neck squamous cell carcinoma, Cancer

Failed

Discontinued